News

New data affirms a low rate of hepatitis B vaccination responsiveness among patients with hepatitis B core antibodies.

The study authors said that decentralizing dispensation of hepatitis C treatment re-engages patients.

David I. Bernstein, MD of the University of Cincinnati College of Medicine discusses the recent approval of short ragweed pollen allergen extract tablet (RAGWITEK) for the treatment of children and adolescents.

New data find significant associations between every five-year earlier onset of diabetes and a higher hazard rate of dementia, in patients aged 35-75 years old.

There is a need for cost-effective treatments for HCV in low-income countries.

Charles Argoff, MD, leads a discussion on the use of pain contracts versus pain agreements between clinicians and patients to bring about desired outcomes.

Experts discuss the need for and impact of peer-to-peer discussion initiatives, as well as the impact telemedicine utilization has had on the opioid crisis.

The US will send unused vaccines to India to help combat the growing pandemic.

The amount of minimally invasive surgeries has increased between 2010-2017.

A new cross-sectional survey assessment shows patients more severe disease report worse survey outcomes on emotional wellbeing and social activity.

While Janus Kinase inhibitors are a fraction of what’s to come in dermatology, research from AAD VMX 2021 shows they represent the potential of unlocking new capabilities across the field.

Jeffrey Stark, MD, of UCB discusses the promising data being generated by the robust trial program for plaque psoriasis.

An intervention can aid children experiencing severe health effects when exposed to opioid use by parents.

Esther Freeman, MD, PhD, discusses the most frequent cutaneous presentations associated with vaccination.

New data has investigators caution against the discontinuation of ulcerative colitis treatment, due to threat of relapse.

A study out of Boston observes little to no difference in previous biologic prescription and worsened odds of infection nor death during the pandemic.

An assessment of real-world registry data suggest the biologic provides significant benefit outside of clinical trials.

A comparison of pooled phase 3 data showed patients treated with the IL-17A inhibitor fared better than those on ustekinumab, without influence from their PsA status.

A network meta-analysis shows favorability with dupilumab and abrocitinib in efficacy and safety outcomes among adults and adolescents.

The Head of Immunology Medical Affairs at UCB discusses what bimekizumab is and how it works.

The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab.

All patients treated with 2.5 benzoyl peroxide and a stabilized cosmetic retinol saw significant improvement in lesion count reduction after 12 weeks.

Implementing alternative therapies does not mean abandoning conventional medications, stresses Peter Lio, MD. There must be a balance that works for the patient's situation.

Seemal Desai, MD, gives an overview of the most promising research and therapies for patient of color populations.

Lawrence Eichenfield, MD, discusses future prescribing plans and safety assessment for the topical JAK 1/2 inhbitor.

New cross-sectional survey data suggest quality-of-life and psychological outcomes may differ in the most common chronic skin disease patient populations.

The investigative topical cream benefits adolescent and adult skin clearance and itch. A study author discusses keeping it available to patients if it reaches the market.

A post-hoc analysis shows that the human monoclonal antibody was linked to sustained improvements according to different disease measurements through week 52.

Patients who received ixekizumab achieved PASI 90 at a median of 43.0 days and PASI 100 at 85.0 days.

In a Q&A, Peter Lio, MD, discusses some evidence for using integrative therapies with patients.